JPRN-UMIN000020094招募中未知
Tolvaptan as A treatment for Refractory Cirrhotic Ascites in Japanese population (TARCAJa study) - Tolvaptan as A treatment for Refractory Cirrhotic Ascites in Japanese population(TARCAja study)
Mitsui Memorail Hospital Department of Gastroenterology0 个研究点目标入组 200 人开始时间: 2015年12月7日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Alergy to tolvaptan. Renal failure patients. Diffcult to drink water. Hypernatremia patients. Heptatic encephalopathy patients. Pregnancy. Other patients who doctors judged as not suitable for this study.
研究者
相似试验
招募中
不适用
Safety and efficacy study of four weeks oral administration of tolvaptan in liver cirrhotic patients with hyponatremia and ascitesDiseases of the digestive systemKCT0000569Konkuk University Medical Center104
进行中（未招募）
不适用
Satavaptan Cirrhotic Ascites Treatment Study a double-blind, randomised, parallel-group comparison of treatment with satavaptan at 5 to 10 mg daily versus placebo on top of conventional treatment in patients with ascites due to cirrhosis of the liver - CATScirrhotic ascitesMedDRA version: 9.1Level: LLTClassification code 10003445Term: AscitesEUCTR2006-000132-27-ITSanofi-Synthelabo Recherche440
进行中（未招募）
不适用
Satavaptan Cirrhotic Ascites Treatment Study: a double-blind, randomised, parallel-group comparison of treatment with satavaptan at 5 to 10 mg daily versus placebo on top of conventional treatment in patients with ascites due to cirrhosis of the liver - CATSEUCTR2006-000132-27-SEsanofi-aventis R&D440
进行中（未招募）
1 期
Satavaptan Cirrhotic Ascites Treatment Study: a double-blind, randomised, parallel-group comparison of treatment with satavaptan at 5 to 10 mg daily versus placebo on top of conventional treatment in patients with ascites due to cirrhosis of the liver - CATSCirrhotic ascitesMedDRA version: 8.1Level: LLTClassification code 10003445EUCTR2006-000132-27-NLsanofi-aventis R&D440
进行中（未招募）
不适用
Satavaptan Cirrhotic Ascites Treatment Study: a double-blind, randomised, parallel-group comparison of treatment with satavaptan at 5 to 10 mg daily versus placebo on top of conventional treatment in patients with ascites due to cirrhosis of the liver - CATSCirrhotic ascitesMedDRA version: 8.1Level: LLTClassification code 10003445EUCTR2006-000132-27-BESanofi-aventis R&D440